Skip to main content
. 2018 Aug 1;8(8):180098. doi: 10.1098/rsob.180098

Figure 4.

Figure 4.

Mechanisms of resistance to SMO inhibitors. Three mechanisms of acquired resistance to SMO inhibitors have been identified in tumours, all of which result in downstream activation of the pathway. (a) Mutation of SMO in the drug-binding site leads to loss of inhibition. (b) Loss of SUFU leads to downstream activation of the pathway. (c) Amplification of GLI1, or GLI2, leads to increased expression and downstream activation of the HH pathway.